Synthesis and biological activity of glycyrrhetinic acid derivatives as antitumor agents. 2019

Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing, 100102, China.

Glycyrrhetinic acid (GA) had been the star anticancer lead compound and appealed to many scientists all over the world; however, its antitumor activity was not potent enough. To improve GA's cytoxicity and explore the effect of bonding mode on antitumor activity, 32 compounds including GA-OH series (GO, esters in C-3 position) and GA-NH2 series (GN, with amide linkages in C-3 position) had been designed and synthesized. All the compounds were screened for in vitro cytotoxicity against A549, HepG2, MCF-7, Hela and MDCK cell lines. As a result, all the de-protected (without Boc group) derivatives showed much stronger cytotoxic activity than GA, and surprisingly enough, all the GN series of the compounds were more potent than GO series against various tumor cells. Among them, the compound 26 (amide linkages in C-3 position) exhibited stronger antitumor activity against A549 cell line (IC50 = 2.109 ± 0.11 μM) than the positive drug cisplatin (IC50 = 9.001 ± 0.37 μM). Further studies indicated that compound 26 could induce A549 apoptosis via nuclei fragmentation. The detection of apoptosis and cell cycle analysis indicated that compound 26 could induce the early apoptosis and prevent A549 cells transition from S to G2 phase. Furthermore, the structure-activity relationships were briefly discussed. Among which, current study displayed amide linkages in C-3 position could effectively enhance GA cytotoxicity, providing a new modification strategy for further study.

UI MeSH Term Description Entries
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006034 Glycyrrhetinic Acid An oleanolic acid from GLYCYRRHIZA that has some antiallergic, antibacterial, and antiviral properties. It is used topically for allergic or infectious skin inflammation and orally for its aldosterone effects in electrolyte regulation. Enoxolone,Glycyrrhetic Acid,Rhetinic Acid,Uralenic Acid,Arthrodont,Glyciram,Glycyram,Jintan,Po 12,12, Po,Acid, Glycyrrhetic,Acid, Glycyrrhetinic,Acid, Rhetinic,Acid, Uralenic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
December 2010, European journal of medicinal chemistry,
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
January 2015, European journal of medicinal chemistry,
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
January 2012, Journal of Asian natural products research,
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
November 2011, European journal of medicinal chemistry,
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
January 2014, Medicinal chemistry (Shariqah (United Arab Emirates)),
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
June 2017, Molecules (Basel, Switzerland),
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
May 2012, Bioorganic & medicinal chemistry letters,
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
January 2021, Molecules (Basel, Switzerland),
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
September 2011, Mini reviews in medicinal chemistry,
Fei Zhou, and Gao-Rong Wu, and De-Sheng Cai, and Bing Xu, and Meng-Meng Yan, and Tao Ma, and Wen-Bo Guo, and Wen-Xi Zhang, and Xue-Mei Huang, and Xiao-Hui Jia, and Yu-Qin Yang, and Feng Gao, and Peng-Long Wang, and Hai-Min Lei
May 2023, Future medicinal chemistry,
Copied contents to your clipboard!